|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: HAUS4 |
Gene summary for HAUS4 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | HAUS4 | Gene ID | 54930 |
| Gene name | HAUS augmin like complex subunit 4 | |
| Gene Alias | C14orf94 | |
| Cytomap | 14q11.2 | |
| Gene Type | protein-coding | GO ID | GO:0000226 | UniProtAcc | Q9H6D7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 54930 | HAUS4 | LZE2T | Human | Esophagus | ESCC | 9.37e-03 | 4.95e-01 | 0.082 |
| 54930 | HAUS4 | LZE4T | Human | Esophagus | ESCC | 5.02e-12 | 3.78e-01 | 0.0811 |
| 54930 | HAUS4 | LZE7T | Human | Esophagus | ESCC | 3.80e-05 | 3.32e-01 | 0.0667 |
| 54930 | HAUS4 | LZE8T | Human | Esophagus | ESCC | 5.67e-08 | 3.28e-01 | 0.067 |
| 54930 | HAUS4 | LZE24T | Human | Esophagus | ESCC | 7.61e-22 | 6.20e-01 | 0.0596 |
| 54930 | HAUS4 | LZE21T | Human | Esophagus | ESCC | 4.96e-03 | 3.25e-01 | 0.0655 |
| 54930 | HAUS4 | LZE6T | Human | Esophagus | ESCC | 3.69e-07 | 3.21e-01 | 0.0845 |
| 54930 | HAUS4 | P1T-E | Human | Esophagus | ESCC | 2.51e-08 | 5.06e-01 | 0.0875 |
| 54930 | HAUS4 | P2T-E | Human | Esophagus | ESCC | 1.45e-34 | 7.14e-01 | 0.1177 |
| 54930 | HAUS4 | P4T-E | Human | Esophagus | ESCC | 2.04e-30 | 8.26e-01 | 0.1323 |
| 54930 | HAUS4 | P5T-E | Human | Esophagus | ESCC | 1.61e-40 | 7.31e-01 | 0.1327 |
| 54930 | HAUS4 | P8T-E | Human | Esophagus | ESCC | 2.36e-20 | 3.98e-01 | 0.0889 |
| 54930 | HAUS4 | P9T-E | Human | Esophagus | ESCC | 5.13e-17 | 4.11e-01 | 0.1131 |
| 54930 | HAUS4 | P10T-E | Human | Esophagus | ESCC | 2.08e-24 | 4.72e-01 | 0.116 |
| 54930 | HAUS4 | P11T-E | Human | Esophagus | ESCC | 7.02e-16 | 7.07e-01 | 0.1426 |
| 54930 | HAUS4 | P12T-E | Human | Esophagus | ESCC | 5.13e-58 | 9.77e-01 | 0.1122 |
| 54930 | HAUS4 | P15T-E | Human | Esophagus | ESCC | 6.86e-61 | 1.42e+00 | 0.1149 |
| 54930 | HAUS4 | P16T-E | Human | Esophagus | ESCC | 4.73e-16 | 4.46e-01 | 0.1153 |
| 54930 | HAUS4 | P17T-E | Human | Esophagus | ESCC | 5.92e-14 | 6.61e-01 | 0.1278 |
| 54930 | HAUS4 | P19T-E | Human | Esophagus | ESCC | 9.62e-10 | 6.29e-01 | 0.1662 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000705114 | Esophagus | ESCC | spindle organization | 134/8552 | 184/18723 | 5.70e-14 | 2.87e-12 | 134 |
| GO:00512256 | Esophagus | ESCC | spindle assembly | 85/8552 | 117/18723 | 2.72e-09 | 5.98e-08 | 85 |
| GO:00070982 | Esophagus | ESCC | centrosome cycle | 85/8552 | 130/18723 | 4.41e-06 | 4.69e-05 | 85 |
| GO:00310233 | Esophagus | ESCC | microtubule organizing center organization | 92/8552 | 143/18723 | 5.04e-06 | 5.31e-05 | 92 |
| GO:000705111 | Liver | HCC | spindle organization | 116/7958 | 184/18723 | 1.40e-08 | 3.40e-07 | 116 |
| GO:005122511 | Liver | HCC | spindle assembly | 75/7958 | 117/18723 | 1.92e-06 | 2.67e-05 | 75 |
| GO:0031023 | Liver | HCC | microtubule organizing center organization | 82/7958 | 143/18723 | 2.38e-04 | 1.79e-03 | 82 |
| GO:0007098 | Liver | HCC | centrosome cycle | 75/7958 | 130/18723 | 3.33e-04 | 2.34e-03 | 75 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| HAUS4 | SNV | Missense_Mutation | novel | c.499G>A | p.Glu167Lys | p.E167K | Q9H6D7 | protein_coding | tolerated(0.12) | benign(0.015) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| HAUS4 | SNV | Missense_Mutation | c.688A>G | p.Lys230Glu | p.K230E | Q9H6D7 | protein_coding | deleterious(0.01) | benign(0.053) | TCGA-B6-A0IJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| HAUS4 | SNV | Missense_Mutation | c.77N>T | p.Pro26Leu | p.P26L | Q9H6D7 | protein_coding | tolerated(1) | probably_damaging(0.999) | TCGA-E2-A14Z-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | PD | |
| HAUS4 | SNV | Missense_Mutation | novel | c.343N>A | p.Leu115Ile | p.L115I | Q9H6D7 | protein_coding | deleterious(0.04) | probably_damaging(0.994) | TCGA-GI-A2C9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | SD | |
| HAUS4 | SNV | Missense_Mutation | c.773C>G | p.Ser258Cys | p.S258C | Q9H6D7 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD | |
| HAUS4 | insertion | In_Frame_Ins | novel | c.650_651insAGT | p.Lys217_Ser218insVal | p.K217_S218insV | Q9H6D7 | protein_coding | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD | ||
| HAUS4 | SNV | Missense_Mutation | rs757985683 | c.1027N>A | p.Val343Ile | p.V343I | Q9H6D7 | protein_coding | deleterious(0.01) | benign(0.046) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| HAUS4 | SNV | Missense_Mutation | novel | c.911A>G | p.Asp304Gly | p.D304G | Q9H6D7 | protein_coding | deleterious(0.04) | probably_damaging(0.995) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| HAUS4 | deletion | Frame_Shift_Del | c.521delA | p.Lys174ArgfsTer21 | p.K174Rfs*21 | Q9H6D7 | protein_coding | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |||
| HAUS4 | SNV | Missense_Mutation | novel | c.708G>T | p.Gln236His | p.Q236H | Q9H6D7 | protein_coding | tolerated(0.14) | probably_damaging(0.994) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |